Polymeric micelles using cholinium-based ionic liquids for the encapsulation and release of hydrophobic drug molecules. (27th January 2021)

• Record Type: Journal Article
• Authors: Kurnik, Isabelle S.; D'Angelo, Natália A.; Mazzola, Priscila G.; Chorilli, Marlus; Kamei, Daniel T.; Pereira, Jorge F. B.; Vicente, António A.; Lopes, André M.
• Is Part Of: Biomaterials science. Volume 9:Number 6(2021)
• Page Start: 2183
• Page End: 2196
• Publication Date: 2021-01-27
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1039/d0bm01884h
• Languages: English
• ISSNs: 2047-4830

Abstract

Abstract : We generated stable amphiphilic copolymer-based polymeric micelles (PMs) with temperature-responsive properties utilizing Pluronic® L35 and a variety of ionic liquids (ILs) for the encapsulation and release of curcumin. Abstract : We generated stable amphiphilic copolymer-based polymeric micelles (PMs) with temperature-responsive properties utilizing Pluronic® L35 and a variety of ionic liquids (ILs) to generate different aqueous two-phase micellar systems (ATPMSs). The partitioning of the hydrophobic model compound curcumin (CCM) into the PM-rich phase and the drug delivery capabilities of the PMs were investigated. ATPMSs formed using more hydrophobic ILs ( i.e., [Ch][Hex] ≈ [Ch][But] > [Ch][Pro] > [Ch][Ac] ≈ [Ch]Cl) were the most effective in partitioning ( K CCM ) and recovering ( REC Rich ) CCM into the PM-rich phase (15.2 < K CCM < 22.0 and 90% < REC Rich < 95%, respectively). Moreover, using 1.2 M [Ch][But] and 0.2 M [Ch][Hex] ILs yielded higher encapsulation efficiency ( EE ) (94.1 and 96.0%, respectively) and drug loading ( DL ) capacity (14.8 and 16.2%, respectively), together with an increase in the average hydrodynamic diameter of the PMs ( D H ) (42.5 and 45.6 nm, respectively). The CCM–PM formulations were stable at 4.0, 25.0, and 37.0 °C and the release of CCM was faster with the less hydrophobic ILs ( i.e., [Ch]Cl and [Ch][Ac]). Furthermore, due to the lower critical solution temperature properties of Pluronic® L35, the PMs exhibit temperature responsiveness at 37.0 °C. In vitro cytotoxicity assays were also performed to determine the potency of CCM–PM formulations, and a 1.8-fold decrease in IC 50 values was observed between the CCM–PMs/[Ch][Hex] and CCM–PMs/[Ch]Cl formulations for PC3 cells. The lower IC 50 value for the [Ch][Hex] version corresponded to a greater potency compared to the [Ch]Cl version, since a lower concentration of CCM was required to achieve the same therapeutic effect. The ATPMSs investigated in this study serve as a novel platform for Pluronic® L35/PBS buffer (pH 7.4) + IL-based ATPMS development. The unique properties reported here may be useful in applications such as controlled-release drug delivery systems (DDS), encapsulation, and bioseparations.